Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Change in Receivables (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of Change in Receivables data on record, last reported at -$54000.0 in Q3 2025.

  • For Q3 2025, Change in Receivables fell 254.29% year-over-year to -$54000.0; the TTM value through Sep 2025 reached -$38000.0, up 89.67%, while the annual FY2024 figure was $49000.0, 108.72% up from the prior year.
  • Change in Receivables reached -$54000.0 in Q3 2025 per CRVS's latest filing, down from $7000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $130000.0 in Q3 2022 and bottomed at -$429000.0 in Q2 2023.
  • Average Change in Receivables over 4 years is -$40333.3, with a median of $6000.0 recorded in 2024.
  • Peak YoY movement for Change in Receivables: soared 218.18% in 2024, then crashed 254.29% in 2025.
  • A 4-year view of Change in Receivables shows it stood at $85000.0 in 2022, then plummeted by 82.35% to $15000.0 in 2023, then tumbled by 66.67% to $5000.0 in 2024, then tumbled by 1180.0% to -$54000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were -$54000.0 in Q3 2025, $7000.0 in Q2 2025, and $4000.0 in Q1 2025.